PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1455607
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1455607
The Middle East and Africa pharmacogenetics testing in psychiatry/depression market is expected to reach USD 59.30 thousand by 2031 from USD 132.56 thousand in 2023, growing with a CAGR of 8.0 % in the forecast period of 2024 to 2034.
Middle East and Africa Pharmacogenetics Testing in Psychiatry/Depression Market, By Type (Anxiety, Mood Disorders, Depression, Bipolar Disorders, Psychotic Disorders, and Eating Disorders), Test Type (Whole Genome Sequencing and Chromosomal Array-Based Tests), Patient Type (Child, Adults, and Geriatric), Gene Type (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and Others), Products (Instruments, Consumables, and Software and Services), End User (Hospitals and Clinics, Diagnostics Laboratories, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distribution, Hospital Pharmacy, and Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031